Mayinglong Pharmaceutical Group Co's quarterly market cap
increased
from Sep. 2025 (¥11,401 Mil) to Dec. 2025 (¥12,070 Mil) but then
declined
from Dec. 2025 (¥12,070 Mil) to Mar. 2026 (¥10,841 Mil).
Mayinglong Pharmaceutical Group Co's annual market cap
increased
from Dec. 2023 (¥10,423 Mil) to Dec. 2024 (¥11,255 Mil) and
increased
from Dec. 2024 (¥11,255 Mil) to Dec. 2025 (¥12,070 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Mayinglong Pharmaceutical Group Co's Enterprise Value for Today is ¥7,707 Mil.
Mayinglong Pharmaceutical Group Co (SHSE:600993) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Mayinglong Pharmaceutical Group Co Market Cap Related Terms
Mayinglong Pharmaceutical Group Co Market Cap Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mayinglong Pharmaceutical Group Co Market Cap Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Mayinglong Pharmaceutical Group Co's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mayinglong Pharmaceutical Group Co Market Cap vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Mayinglong Pharmaceutical Group Co's Market Cap distribution charts can be found below:
* The bar in red indicates where Mayinglong Pharmaceutical Group Co's Market Cap falls into.
Mayinglong Pharmaceutical Group Co Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mayinglong Pharmaceutical Group Co (SHSE:600993) has a Market Cap of ¥10,022 Mil as of Jul. 12, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Mayinglong Pharmaceutical Group Co and its competitors. According to the industry distribution chart, Mayinglong Pharmaceutical Group Co ranks #199 out of 1024 companies in the Drug Manufacturers industry, placing it in the top 19.4%.
Is Mayinglong Pharmaceutical Group Co's Market Cap too high?
Mayinglong Pharmaceutical Group Co's current Market Cap is ¥10,022 Mil. Based on the distribution chart, Mayinglong Pharmaceutical Group Co ranks #199 out of 1024 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Mayinglong Pharmaceutical Group Co has a GF Score™ of 92/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Mayinglong Pharmaceutical Group Co's Market Cap compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Mayinglong Pharmaceutical Group Co ranks #199 out of 1024 companies for Market Cap. This places Mayinglong Pharmaceutical Group Co in the top 19% of its industry — outperforming the majority of peers. The industry median Market Cap is 213.52. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 213.52, based on 1,024 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Mayinglong Pharmaceutical Group Co and its competitors. For the Drug Manufacturers industry, the median Market Cap is 213.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mayinglong Pharmaceutical Group Co's current Market Cap is ¥10,022 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mayinglong Pharmaceutical Group Co stock overvalued right now?
Based on GuruFocus' analysis, Mayinglong Pharmaceutical Group Co (SHSE:600993) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥29.53, compared to a current price of ¥23.25 — trading 21.3% below its estimated fair value. The current Market Cap is ¥10,022 Mil. Mayinglong Pharmaceutical Group Co's overall GF Score™ is 92/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Mayinglong Pharmaceutical Group Co (SHSE:600993), the current Market Cap is ¥10,022 Mil as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mayinglong Pharmaceutical Group Co (SHSE:600993) Overvalued in 2026?
Based on GuruFocus' analysis, Mayinglong Pharmaceutical Group Co stock appears to be undervalued.
The current stock price of ¥23.25 is trading 21.3% below its estimated GF Value™ of ¥29.53.
GuruFocus considers Mayinglong Pharmaceutical Group Co to be Modestly Undervalued.
Key valuation signals for SHSE:600993:
Market Cap: ¥10,022 Mil
GF Value™: ¥29.53 vs. price of ¥23.25 (21.3% below fair value)
No single metric tells the full story. See the SHSE:600993 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mayinglong Pharmaceutical Group Co Business Description
Mayinglong Pharmaceutical Group Co Ltd is a China-based company mainly involved in pharmaceutical development, retailing and wholesaling. The company provides ointments, suppositories, and tablets for hemorrhoids.
92GF Score
Get the complete analysis for SHSE:600993
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600993 has been successfully added to your 
